Ebixa
memantine
Memantine hydrochloride
Keep this leaflet. You may need to read it again.
If you have any further questions, ask your doctor or pharmacist.
This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.
What Ebixa is and what it is used for
What you need to know before you take Ebixa
How to take Ebixa
Possible side effects
How to store Ebixa
Contents of the pack and other information
Ebixa contains the active substance memantine hydrochloride. It belongs to a group of medicines known as anti-dementia medicines.
Memory loss in Alzheimer’s disease is due to a disturbance of message signals in the brain. The brain contains so-called N-methyl-D-aspartate (NMDA)-receptors that are involved in transmitting nerve
signals important in learning and memory. Ebixa belongs to a group of medicines called NMDA- receptor antagonists. Ebixa acts on these NMDA-receptors improving the transmission of nerve signals and the memory.
Ebixa is used for the treatment of patients with moderate to severe Alzheimer’s disease.
- if you are allergic to memantine or any of the other ingredients of this medicine (listed in section 6).
Talk to your doctor or pharmacist before taking Ebixa:
if you have a history of epileptic seizures
if you have recently experienced a myocardial infarction (heart attack), or if you are suffering from congestive heart failure or from an uncontrolled hypertension (high blood pressure).
In these situations the treatment should be carefully supervised, and the clinical benefit of Ebixa reassessed by your doctor on a regular basis.
If you suffer from renal impairment (kidney problems), your doctor should closely monitor your kidney function and if necessary adapt the memantine doses accordingly.
If you are suffering from states of renal tubulary acidosis (RTA, an excess of acid-forming substances in the blood due to renal dysfunction (poor kidney function)) or severe infections of the urinary tract (structure that carries urine), your doctor may need to adjust the dose of your medicine.
The use of medicinal products called amantadine (for the treatment of Parkinson’s disease), ketamine (a substance generally used as an anaesthetic), dextromethorphan (generally used to treat cough) and other NMDA-antagonists at the same time should be avoided.
Ebixa is not recommended for children and adolescents under the age of 18 years.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
In particular, Ebixa may change the effects of the following medicines and their dose may need to be adjusted by your doctor:
amantadine, ketamine, dextromethorphan
dantrolene, baclofen
cimetidine, ranitidine, procainamide, quinidine, quinine, nicotine
hydrochlorothiazide (or any combination with hydrochlorothiazide)
anticholinergics (substances generally used to treat movement disorders or intestinal cramps)
anticonvulsants (substances used to prevent and relieve seizures)
barbiturates (substances generally used to induce sleep)
dopaminergic agonists (substances such as L-dopa, bromocriptine)
neuroleptics (substances used in the treatment of mental disorders)
oral anticoagulants
If you go into hospital, let your doctor know that you are taking Ebixa.
You should inform your doctor if you have recently changed or intend to change your diet substantially (e.g. from normal diet to strict vegetarian diet), as your doctor may need to adjust the dose of your medicine.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
The use of memantine in pregnant women is not recommended.
Women taking Ebixa should not breast-feed.
Your doctor will tell you whether your illness allows you to drive and to use machines safely. Also, Ebixa may change your reactivity, making driving or operating machinery inappropriate.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium- free’.
Always take Ebixa exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
The recommended dose of Ebixa for adults and older people is 20 mg once a day. In order to reduce the risk of side effects this dose is achieved gradually by the following daily treatment scheme:
week 1 | half a 10 mg tablet |
week 2 | one 10 mg tablet |
week 3 | one and a half 10 mg tablets |
week 4 and beyond | two 10 mg tablets once a day |
The usual starting dose is half a tablet once a day (1x 5 mg) for the first week. This is increased to one tablet once a day (1x 10 mg) in the second week and to 1 and a half tablets once a day in the third week. From the fourth week on, the usual dose is 2 tablets once a day (1x 20 mg).
If you have impaired kidney function, your doctor will decide upon a dose that suits your condition. In this case, monitoring of your kidney function should be performed by your doctor at specified intervals.
Ebixa should be administered orally once a day. To benefit from your medicine you should take it regularly every day at the same time of the day. The tablets should be swallowed with some water. The tablets can be taken with or without food.
Continue to take Ebixa as long as it is of benefit to you. Your doctor should assess your treatment on a regular basis.
In general, taking too much Ebixa should not result in any harm to you. You may experience increased symptoms as described in section 4. “Possible side effects”.
If you take a large overdose of Ebixa, contact your doctor or get medical advice, as you may need medical attention.
If you find you have forgotten to take your dose of Ebixa, wait and take your next dose at the usual time.
Do not take a double dose to make up for a forgotten dose.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. In general, the observed side effects are mild to moderate.
Common (affects 1 to 10 users in 100):
Headache, sleepiness, constipation, elevated liver function tests, dizziness, balance disorders, shortness of breath, high blood pressure and drug hypersensitivity
Uncommon (affects 1 to 10 users in 1,000):
Tiredness, fungal infections, confusion, hallucinations, vomiting, abnormal gait, heart failure and venous blood clotting (thrombosis/thromboembolism)
Very Rare (affects less than 1 user in 10,000):
Seizures
Not known (frequency cannot be estimated from the available data):
Inflammation of the pancreas, inflammation of the liver (hepatitis) and psychotic reactions
Alzheimer’s disease has been associated with depression, suicidal ideation and suicide. These events have been reported in patients treated with Ebixa.
If you get any side effects, talk to your doctor or pharmacis. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and the blister after EXP. The expiry date refers to the last day of that month.
This medicinal product does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
The active substance is memantine hydrochloride. Each film-coated tablet contains 10 mg memantine hydrochloride equivalent to 8.31 mg memantine.
The other ingredients are microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica and magnesium stearate, all in the tablet core; and hypromellose, macrogol 400, titanium dioxide (E171) and iron oxide yellow (E172), all in the tablet coating.
Ebixa film-coated tablets are presented as pale yellow to yellow, oval shaped film-coated tablet with breaking line and engravings “1 0” on one side and “M M” on the other side. The tablet can be divided into equal doses.
Ebixa film-coated tablets are available in blister packs of 14 tablets, 28 tablets, 30 tablets, 42 tablets, 49 x 1 tablets, 50 tablets, 56 tablets, 56 x 1 tablets, 70 tablets, 84 tablets, 98 tablets, 98 x 1 tablets, 100
tablets, 100 x 1 tablets, 112 tablets, 980 (10 x 98) tablets or 1000 (20 x 50) tablets. The pack sizes 49 x
1, 56 x 1, 98 x 1 and 100 x 1 film-coated tablets are presented in unit dose blister.
Not all pack sizes may be marketed.
H. Lundbeck A/S Ottiliavej 9
2500 Valby
Denmark.
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.
H. Lundbeck A/S, Danija Tel: + 45 36301311
Lundbeck Export A/S Representative Office Tel: +359 2 962 4696
Lundbeck S.A.
Tél: +32 2 535 7979
Lundbeck Česká republika s.r.o. Tel: +420 225 275 600
Lundbeck Pharma A/S Tlf: +45 4371 4270
H. Lundbeck A/S, Denmark Tel: + 45 36301311
Lundbeck B.V.
Tel: +31 20 697 1901
Lundbeck Eesti AS Tel: + 372 605 9350
H. Lundbeck AS Tlf: +47 91 300 800
Lundbeck Hellas S.A. Τηλ: +30 210 610 5036
Lundbeck Austria GmbH Tel: +43 1 253 621 6033
Lundbeck España S.A. Tel: +34 93 494 9620
Lundbeck Poland Sp. z o. o. Tel.: + 48 22 626 93 00
Lundbeck SAS
Tél: + 33 1 79 41 29 00
Lundbeck Portugal Lda Tel: +351 21 00 45 900
Lundbeck Croatia d.o.o. Tel.: + 385 1 6448263
Lundbeck (Ireland) Limited Tel: +353 1 468 9800
Lundbeck Romania SRL Tel: +40 21319 88 26
Lundbeck Pharma d.o.o. Tel.: +386 2 229 4500
Vistor hf.
Tel: +354 535 7000
Lundbeck Italia S.p.A. Tel: +39 02 677 4171
Oy H. Lundbeck Ab Puh/Tel: +358 2 276 5000
Lundbeck Hellas A.E Τηλ.: +357 22490305
H. Lundbeck AB Tel: +46 4069 98200
H. Lundbeck A/S, Dānija Tel: + 45 36301311
Lundbeck (Ireland) Limited Tel: +353 1 468 9800